RECRUITING

Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care coordination between pharmacists working in oncology practices and those working in primary care or community practices (Pharmacists Coordinated care Oncology Model \[PCOM\]). This is a pilot study in which the investigators will examine the association between outcome measures, but the study design and sample size are insufficient to quantify the impact of OAA initiation or OAA adherence on adherence to chronic medications. This pilot study and data analyses are being done in preparation for a larger, controlled study.

Official Title

Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

Quick Facts

Study Start:2021-02-08
Study Completion:2023-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04663100

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Receiving cancer care at Vanderbilt University Medical Center
  2. * Diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), chronic myeloid leukemia (CML), or multiple myeloma (MM)
  3. * Initiating an oral anticancer agent, either for the first time or a change from previous oral agent
  4. * Diagnosis of 2 chronic conditions, including at least one of the following: diabetes, hypertension, hyperlipidemia, congestive heart failure, depression/anxiety, gastroesophageal reflux disease, and/or chronic obstructive pulmonary disease
  5. * Patients taking at least two chronic medications, including at least one medication for one of the conditions listed above.
  6. * Willing and able to sign informed consent.
  1. * Cannot communicate in English
  2. * Concurrent diagnosis of type 1 diabetes or human immunodeficiency virus

Contacts and Locations

Study Contact

Justin Gatwood, PhD
CONTACT
6155323403
jgatwood@uthsc.edu
Katie Gatwood, PharmD
CONTACT
6153433836
katie.s.gatwood@vumc.org

Study Locations (Sites)

Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States

Collaborators and Investigators

Sponsor: University of Tennessee

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-02-08
Study Completion Date2023-12-31

Study Record Updates

Study Start Date2021-02-08
Study Completion Date2023-12-31

Terms related to this study

Keywords Provided by Researchers

  • adherence
  • leukemia
  • anticancer agents
  • chronic disease management
  • pharmacy practice
  • hematological malignancy

Additional Relevant MeSH Terms

  • Chronic Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Multiple Myeloma
  • Multiple Chronic Conditions